Clinical Trials Browser

Interventional × milatuzumab × Lymphoid × Clear all

NCT01585688 2021-10-08

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01663766 2021-08-19

Phase I Study of Milatuzumab for Graft Versus Host Disease

Phase 1 Terminated

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00504972 2018-05-29

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

35 enrolled 11 charts

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00868478 2010-06-02

The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell